SGRY Shareholders: Amparo Law Firm PLLC Is Investigating Whether Surgery Partners's $23.50-Per-Share Sale to HealthSpan Partners Delivers the Best Value for Shareholders
News originally published by
GlobeNewswireThe firm is also examining whether the proxy statement will leave out material information Surgery Partners shareholders need before they vote.
New York, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Attorney Advertising
Amparo Law Firm PLLC, through its Amparo Investor Rights practice, is investigating whether $23.50 per share is the best price Surgery Partners, Inc. (Nasdaq: SGRY) shareholders could obtain, whether the board ran a sale process designed to get it, and whether shareholders may have claims for additional value. We are also investigating whether the proxy statement gives you every fact Section 14(a) requires so you can judge that price before you vote. The proposed take-private is by HealthSpan Partners.
SGRY shareholders: click here to learn more about your rights and options at no cost or obligation.
THE QUESTION FOR SHAREHOLDERS
HealthSpan Partners, a contractual affiliate and supporting organization of Bon Secours Mercy Health has agreed to acquire Surgery Partners for $23.50 per share in cash for shareholders other than affiliates of Bain Capital, who will instead roll over their shares into equity interests in the acquiring entity, and the company gives the deal value as enterprise value of approximately $5.7 billion.
Before you vote, you should be able to see how the board chose this buyer and this number, what other options it weighed, and what its financial advisors concluded.
THE DEAL AT A GLANCE
- Buyer: HealthSpan Partners, a contractual affiliate and supporting organization of Bon Secours Mercy Health
- Price: $23.50 per share in cash for shareholders other than affiliates of Bain Capital
- Deal value: About $5.7 billion enterprise value (company-stated)
- Announced: October 26, 2026
- Shareholder vote: Not yet scheduled
- Expected closing: First quarter of 2027
WHAT WE ARE INVESTIGATING
- The price. Whether $23.50 per share is the best price shareholders could obtain, and whether shareholders may have claims for additional value.
- The sale process. How the board ran the sale process and whether it looked for other buyers.
- The advisors. The financial advisors' fees and any ties they have to the buyer.
- The disclosures. Whether the proxy statement gives you every fact Section 14(a) requires so you can judge that price before you vote.
WHY TIMING MATTERS
Shareholders usually have the most options before a deal goes to a vote. a Special Committee of the Surgery Partners Board of Directors, composed entirely of independent and disinterested directors, led the negotiations and unanimously recommended the deal; Bain Capital, which SGRY describes as its largest shareholder owning approximately 39% of outstanding shares, agreed to vote its shares in favor of the transaction. The shareholder vote has not yet been scheduled.
TALK TO US ABOUT YOUR SGRY SHARES
amparoinvestorrights.com/actions/surgery-partners-inc/
or call (888) 577-7817
No cost to speak with us. We speak English and Spanish.
You do not need to buy or sell shares to contact us.
QUESTIONS SHAREHOLDERS ASK
Does it cost anything?
Amparo Investor Rights handles shareholder matters on a contingency basis. You pay no fees or costs unless there is a recovery.
Is contacting you confidential?
We keep your communications with us confidential. Contacting the firm does not create an attorney-client relationship.
What happens next?
An attorney reviews your information and follows up with you.
ABOUT THE ATTORNEY
The practice is led by Bob Amirian, Esq., Founding Partner of Amparo Law Firm. A graduate of Georgetown University Law Center and a summa cum laude graduate of UCLA, he served as a law clerk to Chief Judge Sharon Prost of the U.S. Court of Appeals for the Federal Circuit and practiced at Venable LLP.
About Amparo Investor Rights: Amparo Investor Rights is the securities practice of Amparo Law Firm PLLC, a New York law firm that represents investors in shareholder investigations, merger disclosure claims and securities litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome. Contacting the firm does not create an attorney-client relationship. Responsible attorney: Bob Amirian, Esq., Amparo Law Firm PLLC, 40 Wall Street, 28th Floor, New York, NY 10005, (888) 577-7817. Amparo Law Firm PLLC is licensed to practice law in New York, California, Texas, and the District of Columbia.
Contact: Amparo Investor Rights, (888) 577-7817, intake@amparolawfirm.com

Amparo Investor Rights, (888) 577-7817
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.